Skip to main content
. 2022 Oct 19;14(20):5128. doi: 10.3390/cancers14205128

Figure 3.

Figure 3

Progression-free survival (PFS) for all 29 patients from time of diagnosis of recurrence that prompted MEMMAT-like therapy. Median PFS was 22.1 months (KI 6-39).